Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2009 Sep;13(9):1161-6.

Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.

Author information

1
Clinical Trial Centre, Kyungpook National University Hospital, Daegu, Korea; Department of Molecular Medicine, Kyungpook National University School of Medicine, Daegu, Korea.

Abstract

SETTING:

National Masan Tuberculosis Hospital, Masan, South Korea.

OBJECTIVE:

To evaluate the pharmacokinetics of prothionamide (PTH) in South Korean patients with multidrug-resistant tuberculosis (MDR-TB) and to investigate whether differences in body mass index (BMI) could explain observed differences in PTH disposition.

DESIGN:

Seventeen patients participated in the study; all had MDR-TB and had received combination anti-tuberculosis treatment, including PTH, cycloserine, ofloxacin, para-aminosalicylic acid and streptomycin or kanamycin, for at least 2 weeks. The patients were divided into two groups based on BMI: Group A (18.5 < or = BMI<23), and Group B (BMI<18.5). Serum samples were collected over 24 h, and the plasma PTH concentration was determined by a validated high-performance liquid chromatography assay.

RESULTS:

After steady-state administration of PTH, the mean area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12h)) was 11.0 +/- 3.7 microg h/ml. The mean T(max) and t(1/2) were respectively 3.6 h and 2.7 h. No significant difference in PTH disposition was observed between groups A and B, except for ke and t(1/2).

CONCLUSION:

In the pharmacokinetic parameter estimates for PTH in MDR-TB patients during routine treatment, the pharmacokinetics of PTH did not appear to correlate with extent of emaciation in MDR-TB patients.

PMID:
19723408
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center